UroGen Pharma Ltd (NASDAQ: URGN) is -7.67% lower on its value in year-to-date trading and has touched a low of $10.60 and a high of $20.70 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The URGN stock was last observed hovering at around $13.10 in the last trading session, with the day’s gains setting it 0.75%.
Currently trading at $13.85, the stock is 0.94% and -7.67% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.99 million and changing 5.73% at the moment leaves the stock -8.55% off its SMA200. URGN registered -14.98% loss for a year compared to 6-month gain of -7.42%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -7.67% loss in the last 1 month and extending the period to 3 months gives it a -10.47%, and is 6.13% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.23% over the week and 5.28% over the month.
UroGen Pharma Ltd (URGN) has around 201 employees, a market worth around $583.22M and $85.01M in sales. Profit margin for the company is -133.61%. Distance from 52-week low is 30.66% and -33.09% from its 52-week high. The company has generated returns on investments over the last 12 months (-88.36%).
The EPS is expected to grow by 2.16% this year
162.0 institutions hold shares in UroGen Pharma Ltd (URGN), with institutional investors hold 102.85% of the company’s shares. The shares outstanding are 42.11M, and float is at 38.20M with Short Float at 16.87%. Institutions hold 93.39% of the Float.
The top institutional shareholder in the company is RTW INVESTMENTS, LP with over 3.56 million shares valued at $59.69 million. The investor’s holdings represent 10.6572 of the URGN Shares outstanding. As of 2024-06-30, the second largest holder is ADAGE CAPITAL PARTNERS GP, L.L.C. with 3.3 million shares valued at $55.37 million to account for 9.8862 of the shares outstanding. The other top investors are RA CAPITAL MANAGEMENT, L.P. which holds 3.08 million shares representing 9.2374 and valued at over $51.74 million, while GREAT POINT PARTNERS LLC holds 8.7066 of the shares totaling 2.91 million with a market value of $48.77 million.
UroGen Pharma Ltd (URGN) Insider Activity
The most recent transaction is an insider sale by Schoenberg Mark, the company’s Chief Medical Officer. SEC filings show that Schoenberg Mark sold 859 shares of the company’s common stock on Sep 09 ’24 at a price of $13.08 per share for a total of $11236.0. Following the sale, the insider now owns 0.15 million shares.
UroGen Pharma Ltd disclosed in a document filed with the SEC on Sep 09 ’24 that Smith Jason Drew (General Counsel) sold a total of 1,521 shares of the company’s common stock. The trade occurred on Sep 09 ’24 and was made at $13.08 per share for $19895.0. Following the transaction, the insider now directly holds 25226.0 shares of the URGN stock.
Still, SEC filings show that on Sep 09 ’24, Schoenberg Mark (Officer) Proposed Sale 859 shares at an average price of $13.23 for $11365.0. The insider now directly holds shares of UroGen Pharma Ltd (URGN).
